Genome wide association studies implicate a variant in the neuronal nitric oxide synthase adaptor protein (CAPON) in electrocardiographic QT variation and sudden cardiac death.
Introduction
Large genome wide association (GWAS) studies have implicated the neuronal nitric oxide synthase adaptor protein (NOS1-AP) CAPON as a potential molecular marker of both corrected QT interval on the electrocardiogram (ECG), and increased risk of sudden cardiac death [1] [2] [3] [4] [5] .
Single nucleotide polymorphisms (SNPs) in the CAPON gene have also been shown to be an important risk modifier in patients with inherited long QT syndrome [6] [7] [8] where sympathetic drive further exacerbates the electrophysiological phenotype 9 .
In ventricular myocytes CAPON is co-localised with neuronal nitric oxide synthase (nNOS/NOS1) 10, 11 . Increasing CAPON expression using adenoviral gene transfer accelerates cardiac repolarization (shortening action potential duration) by suppressing the L-type calcium current I Ca,L and enhancing the delayed rectifier potassium current I Kr 10 . Furthermore, CAPON facilitates nNOS translocation to caveolae post myocardial infarction (MI), suggesting the interaction with CAPON is required for nNOS redistribution in injured myocardium 12 .
CAPON was first identified in neuronal tissue, where it interacts with the N-terminal PDZ domain of nNOS via C-terminus competition with PSD95 13 . CAPON escorts nNOS to specific target proteins, such as synapsin 14 and the small monomeric G protein, Dexras1 15 , and thus may play an important role in calcium dependent exocytosis. Taken together with the observation that nNOS generated NO acts via cGMP and phosphodiesterase 2 16 to reduce cAMP-protein kinase A dependent neuronal calcium handling and cardiac norepinephrine (NE) release 17, 18 , it is therefore conceivable that an impaired neuronal CAPON-nNOS interaction might augment cardiac sympathetic neurotransmission.
We hypothesized that CAPON is present, but is reduced in cardiac sympathetic neurons from an animal model of dysautonomia 19 . As a consequence this contributes to a pre-disease neuronal phenotype that modulates enhanced calcium handling and neurotransmission. By developing an adenoviral vector with a noradrenergic neuron specific promoter to increase CAPON expression, we also tested the hypothesis that CAPON reduces the neuronal calcium current, intracellular calcium transient and cardiac NE release through an nNOS-cGMP dependent pathway.
Methods
Age-and weight-matched pre-hypertensive young male SHRs (n=51) and normotensive WistarKyoto (WKY; n=45) rats were purchased from Harlan (Bicester, UK) and housed under standard laboratory conditions. This investigation conformed to the 
Sympathetic stellate neuron isolation
Sympathetic neurons were isolated and cultured using a previously published method 20 and the media used for isolation were based on modification of those previously described 21 . Briefly, cardiac stellate ganglia were dissected, de-sheathed and enzymatically digested. Following a sequential mechanical trituration, cell suspension containing stellate neurons was plated onto poly-D/lysine/laminin coated coverslips.
Adenovirus vector transduction
A novel adenoviral vector expressing CAPON fused in frame at the C-terminal end to red fluorescent protein mCherry with either a CMV promoter (Ad.CMV-mCherry/CAPON) or a noradrenergic cell specific promoter (Ad.PRSx8-mCherry/CAPON) were transferred to isolated cardiac sympathetic neurons or whole stellate ganglia tissue. An adenoviral vector expressing only mCherry (Ad.CMV-mCherry or Ad.PRSx8-mCherry) served as a control. 2×10 9 pfu of adenoviral vector was used to infect neurons or ganglia in a 4-well-pate (1.9 cm 2 /well, Nunc, Denmark). The virus-containing medium was left in the well for a maximum of 12 hours before replacing with fresh plating medium. The experiments were performed after 3 days post gene transfer for calcium transient measurements, and after 12 hours for measuring the calcium current, because of the necessity to minimize space clamp error caused by dendritic growth.
For the local evoked norepinephrine release experiment, targeted percutaneous gene transfer to the right atrium was performed under isoflurane (Isocare, Animalcare Ltd) anesthesia (4% for induction and 2-3% for maintenance in 100% O 2 ), using a technique similar to that described previously 22 . Animals received an injection of 1.6×10 10 pfu of Ad.PRSx8-mCherry/CAPON or Ad.PRSx8-mCherry in 300 µl of PBS. Molecular and physiological phenotyping were investigated 5 days after gene transfer.
Immunofluorescence
Cultured primary neurons were fixed in cold acetone/methanol for 10 minutes. After permeabilization and blocking with 0.1% Triton X100 in PBS containing 1% BSA for 1 hour, the neurons were then incubated with primary antibody against CAPON (rabbit pAb, 
Western blotting
Protein extraction and Western blotting were performed as previously described 20 . Details in Supplement.
Patch-clamp recordings
Cells were patched on freshly isolated neurons for non gene transferred experiments. Calcium current was recorded using conventional whole cell techniques. Pipette resistance varied from to test potentials over the range of -50 to +50 mV in 10 mV increments.
Measurement of intracellular calcium concentration
Intracellular free calcium concentration [Ca 2+ ] i of individual cultured stellate neurons was determined using Fura-2 acetoxymethyl ester (Fura-2/AM) fluorescence ratio imaging as previously described 19 . The specific nNOS inhibitor, N-[(4S)-4-Amino-5-[(2-aminoetyl)amino]pentyl]-N'-nitroguanidine (AAAN, 10 µmol/L) was introduced separately after the first high K + (50 mmol/L) stimulation (S1) to depolarize cell as previously described 20 . After 10 minutes of incubation, neurons were stimulated again in the presence of the drug (S2).
Measurement of tissue NOS activity
The activity of NOS was assessed by measuring the conversion of
Citrulline as described previously 23, 24 . Stellates from 2 animals were pooled to provide protein for each NOS activity measure.
Measurement of tissue cGMP levels
Stellate ganglia tissue were isolated and transduced in 4 well plates which contained 2×10 9 pfu of adenoviral vector in 1 ml plating medium that was kept at 37 o C in 5% CO 2 . The virus containing medium was left in the well for a maximum of 12 hours before replacing with fresh plating medium. After 5 days of gene transfer, stellate ganglia were rapidly frozen in liquid nitrogen. Measurement of cGMP levels were performed using cGMP Direct Immunoassay Kit (Abcam) according to the manufacturer's instructions.
Measurement of atrial [ 3 H]-norepinephrine release
Spontaneously beating atria were isolated and transferred to a preheated (37±0.2ºC), constantly oxygenated (carbogen: 95% oxygen, 5% CO 2 ), water-jacketed organ bath containing 3 ml
Tyrode solution where they were pinned flat on a silver stimulating electrode. The method for determining the local release of 3 H-NE to field stimulation (5Hz, 20V. 1ms pulse width, for 1 min) was identical to that which we have previously described 18 .
Data analysis
Data are expressed as mean ± standard error of the mean. All data passed a normality test (Shapiro-Wilk). Comparison within groups was performed using the paired Student's t-test and between groups using the unpaired Student's t test, or ANOVA with Newman-Keuls post hoc analysis for multiple comparisons. P values <0.05 were considered statistically significant.
Results

Identification of endogenous CAPON protein in cardiac sympathetic neurons
Immunostaining demonstrated endogenous CAPON protein co-localised in tyrosine hydroxylase 
Calcium current and intracellular free calcium transients in cardiac sympathetic neurons.
In order to explore whether CAPON overexpression also modulates the neuronal calcium current 
Cardiac norepinephrine release
Percutaneous gene transfer targeted to the right atrium of SHR in vivo also increased CAPON protein expression from right atria as assessed by Western blot (Figure 6A) Here we observed significant CAPON expression in both WKY and SHR stellate neurons, however levels were significantly reduced in pre-hypertensive SHR neurons. Interestingly,
CAPON is also present in ChAT positive intracardiac neurons (unpublished), although it is
unknown whether it impacts on the sympathetic phenotype reported here.
nNOS-CAPON signaling in the pre-hypertensive SHR
Sympathetic hyperactivity and parasympathetic insufficiency is correlated with mortality in patients with and without cardiovascular disease 31-33 . In particular, over-activity of the sympathetic nervous system is implicated in the etiology of human essential hypertension 34-40 .
This has also been observed in an animal of model of genetic hypertension, the SHR, as early as 20 , and given that CAPON acts as a modifier of nNOS in brain neurons,
we suspected that CAPON might also play a role in calcium handling and NE release in cardiac sympathetic neurons. Although the role of CAPON as an inhibitor or mediator of nNOS function in human disease has been widely debated 46 , in our study, overexpression of CAPON increased neuronal nNOS activity and cGMP levels in the SHR, whilst stabilizing nNOS protein expression. This is similar to that seen in isolated ventricular myocytes where CAPON enhanced NOS enzymatic activity and NO release 10 . Considering the brief half-life of NO and its high reactivity as a free radical gas, the biological and cellular effects of nNOS-NO signaling may be highly localized and dependent on the subcellular translocation of nNOS between membrane and cytosolic compartments as previously suggested 47 . For example, CAPON plays an important role in directing nNOS to specific target proteins such as synpasin 14 . However, like Chang et al 10 we
cannot rule out the possibility that CAPON also acts through nNOS independent pathways given that CAPON may compete with other PDZ-binding proteins through interaction via its C terminus.
Our electrophysiological experiments could not determine whether CAPON modulation was more important in the neuronal soma or axonal terminal that is more applicable to localized 
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Novelty and Significance
What Is New?
• The neuronal calcium current and intracellular calcium transient are larger in the prohypertensive SHR compared to the WKY rat and this is associated with reduced expression of CAPON.
• Targeted 
